Plasma treatment of cured patients was discontinued in the United States

The U.S. National Institutes of Health announced Tuesday that it is discontinuing clinical trials on the effectiveness of treatment with blood plasma taken from COVID-19 cured people, with no interim results to treat patients who have been diagnosed with the disease but have not been hospitalized. No benefit was shown.

• read more: [EN DIRECT 2 MARS] All progressions of the infection

The trials began in August 2020. More than 500 people attended the hospital emergency room after showing mild or mild symptoms of COVID-19 and did not need to be admitted to the hospital. Participants selected for this study also had risk factors such as obesity, high blood pressure, diabetes or heart disease.

Some received treatment, others a placebo, and then the researchers noted the number of people who needed additional emergency treatment, who were hospitalized or died within the next 15 days.

A team evaluating the data wrote in a statement (NIH) that “if there is no harm to active plasma, it is unlikely to benefit the patient group.”

The fluid portion of the recovered patient’s blood is called convex plasma, which accumulates antibodies produced by the body to fight the virus after infection.

In late October, a study in India and a study published in the medical journal PMJ concluded that the treatment had “limited efficacy”. According to scientists, this method does not reduce or prevent mortality, making it possible for moderate patients to progress to a more severe case.

More than 100,000 people in the United States have received this treatment since the onset of the epidemic, and many around the world refer to NIH.

In late August, at the urging of Donald Trump, the American Pharmaceuticals (FDA) hastily approved the transfusion of blood plasma into hospitalized patients from those recovered from Covit-19.

Its chairman, Stephen Hahn, was Mr. He admitted that he was wrong during a press conference with Trump, citing statistics that greatly underestimate the benefits of this treatment.

The FDA recently approved its emergency recognition of the use of plasma concentrated only in antibodies, and patients admitted to the hospital showed little improvement in the disease, or hospitalization and impaired ability to produce antibodies.